In the latest news from medical and pharmaceutical field the United States Food and Drug Administration has approved Fycompa (perampanel) tablets to treat partial onset of seizures in epilepsy patients with ages 12 years and older. With this move the patients who were suffering from this disease and waiting for an effective medicine to treat this disease will be contented.

The drug Fycompa has been classified as a scheduled drug by the U.S. Drug Enforcement Administration. The final designation of the scheduled drug will be announced after the final review of the drug. With the final review of the agency the manufacturer Eisai will decide when the drug will be made available to patients and physicians in the United States.

Partial seizures are the most common type of seizure found in patients suffering from epilepsy. The disease is a neural disorder or disorder of the brain in which there is excessive activity and abnormal behavior of the nerve cells of the brain. However, unlike complete seizures, partial seizures affect only a localized area or limited portion of the brain. However, there is every possibility that the effect will spread to other parts of the brain.

Some of the symptoms of seizures are:

  • Repetitive limb movements (spasms)
  • Loss of consciousness.
  • Convulsions
  • Unusual behavior

Some of the side effects or adverse effects that were reported during the clinical trial of the Fycompa 8 mg or 12 mg are:

  • Dizziness
  • Sleepiness
  • Tiredness
  • Nausea
  • Falls
  • Problem with muscle co-ordination
  • Problem while walking
  • Weight gain
  • Vertigo
  • Upper respiratory tract infection
  • Balance disorder
  • Anxiety
  • Blurred vision
  • Stuttering (dysarthria)
  • Excessive sleep (hypersomnia)
  • Agression

Fycompa’s approval was primarily based on three Phase III clinical studies (304, 305 and 306), which were double-blind, multi-center, placebo-controlled, randomized, dose-escalation, parallel group studies to evaluate the safety and efficacy of the drug. The subjects for the trial were patients in the age group 12 years and above and with partial-onset seizures. Throughout the study it was found that Fycompa significantly reduced seizure frequency in patients with partial-onset seizures with or without secondarily generalized seizures.

The drug Fycompa (perampanel) approved by the United States Food And Drug Administration is a receptor antagonist and is an adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in patients. The drug is the first anti-leptic agent approved by the USFDA to work in this manner. The drug was manufactured by Easai Corporation of Japan. Fycompa reduces neuronal hyperexcitation associated with seizures by inhibiting glutamate activity at post-synaptic AMPA receptors.

What is partial onset seizure?

Partial onset seizures generally start up in localized and confined parts of the brain, however, it may spread to other parts of the brain becoming a generalized one. These generalized seizures can further deepen and intensify to cause convulsive seizure also known as tonic-clonic seizure.

Types of partial onset seizures:

Complex partial-onset seizures:

Complex partial-onset seizures usually cause loss of awareness, staring, confusion, and certain movements like hand rubbing, lip smacking, arm positioning, swallowing or uncontrolled shouting.

Simple partial-onset seizures:

Unlike the previous form of seizure, simple partial-onset seizures do not cause a loss of awareness, but they may produce abnormal sensations, such as a funny feeling (an aura), a body movement, unpleasant smell or jerking of the arm.